Clinical Trials Logo

IgG4-related Disease clinical trials

View clinical trials related to IgG4-related Disease.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06285539 Not yet recruiting - Clinical trials for Idiopathic Inflammatory Myopathies

Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases

DRIMID
Start date: March 2024
Phase: Phase 2
Study type: Interventional

Research into novel therapies for rare, immune-mediated inflammatory diseases (IMIDs) is limited due to small patient populations. Patients with Behçet's disease (BD), idiopathic inflammatory myopathy (IIM, also known as myositis) and IgG4-related disease (IgG4-RD) are treated with high-dosed glucocorticoids, methotrexate, azathioprine and mycophenolate mofetil, mostly for long periods of time with attendant risks of long-term toxicity, including infections. Therefore, there is an urgent need for new, more specific anti-inflammatory therapies such as targeted synthetic and biological disease-modifying antirheumatic drugs. Due to the role of type 1 interferon in both BD, IIM and IgG4-RD, JAK-STAT inhibition may be a promising treatment strategy in these conditions, because JAK1 is critical for the signal transduction of pro-inflammatory cytokine receptors. Previous research showed that JAK1 inhibition reduces activation of type 1 interferon-regulated proteins and key chemokines that control tissue inflammation.

NCT ID: NCT05746689 Not yet recruiting - Clinical trials for IgG4-related Disease

Study of Sirolimus in IgG4-related Disease

Start date: March 1, 2023
Phase: N/A
Study type: Interventional

gG4-related disease (IgG4-RD) is a newly recognized systemic autoimmune disease that can involve the pan-creatobiliary tract, retroperitoneum/aorta, head and neck region, and salivary glands, et al. Glucocorticoids are the first-line agents for the treatment of IgG4-RD, however, in order to maintain long-term disease stability and avoid disease relapse, glucocorticoids maintenance therapy should last for a long period, which may induce various glucocorticoid-associated adverse reactions. Sirolimus plays dual roles in inhibiting lymphocyte activation and fibroblast proliferation. It is inferred from its mechanism that sirolimus is a good potential treatment option for IgG4-RD. Therefore, we conducted this single-arm clinical trial on patients with IgG4-RD to determine the efficacy and safety of sirolimus.

NCT ID: NCT05728684 Not yet recruiting - Clinical trials for IgG4 Related Disease

Study to Evaluate the Efficacy and Safety of CM310 in Subjects With IgG4-related Disease

Start date: February 28, 2023
Phase: N/A
Study type: Interventional

This study is a single-arm study initiated to evaluate the efficacy and safety of CM310 in subjects with recurrent IgG4-related disease.

NCT ID: NCT03466970 Not yet recruiting - Clinical trials for IgG4-related Disease

Plasmablast Detection From IgG4-Related Disease Patients

Start date: April 1, 2018
Phase: N/A
Study type: Observational

IgG4-related disease (IgG4-RD) is an immune-mediated, fibro-inflammatory disease that leads to tissue damage, organ dysfunction and, if untreated, to organ failure. The disease can affect almost any anatomic location, but the sites involved most commonly are the pancreas, salivary glands, orbital adnexa, lymph nodes, and retroperitoneum. IgG4-RD, typically diagnosed among individuals who are middle-aged, is characterized by a male predominance except with regard to organs of the head and neck (e.g., the salivary glands and orbits), where the gender distribution is approximately equal. The epidemiology of IgG4-RD remains poorly understood because of its recognition only recently as a multi-organ disease. However, IgG4-RD accounts for many conditions once regarded as disparate, single-organ disorders The purpose of our study is to evaluate the method of plasmablast measurement in peripheral blood of IgG4-RD patients, for diagnosis and follow-up on disease progression and response to treatment. This document will outline the collection, processing and testing procedures for measuring plasmablasts from IgG4-RD patients

NCT ID: NCT03267875 Not yet recruiting - Aortic Aneurysm Clinical Trials

A Laboratory Scan of Patients With Aortic Aneurysms to IgG4 Levels in the Blood

Start date: November 8, 2017
Phase: N/A
Study type: Interventional

IgG4 Related Disease is a multi-systemic fibroenophilic disease that includes a basket of recently discovered medical conditions. The properties that bind them are: lesions similar to tumors in the mixed organs, lymphoplasms filtrate enriched with plasma IgG4 positive cells, storiform fibrosis, and often, but not always, a high level of IgG4 in the serum. This disease has been on the rise for the past two decades and since its recognition in 2001 there has been impressive progress in understanding its various manifestations, so that today almost every body system can be involved. One of the conditions associated with this disease is oritis / periortitis and aneurysms